World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
Luiz Alcino Monteiro GueirosKatherine FranceRachael PoseyJacqueline W MaysBarbara P CareyThomas P SollecitoJane SetterfieldSook Bin WooDonna CultonAimee S PayneGiovanni LodiMartin S GreenbergScott De RossiPublished in: Oral diseases (2020)
There is strong evidence pointing to the efficacy of rituximab in the management of oral disease in SS. Future controlled trials may elucidate the efficacy of belimumab and abatacept. The new drug CFZ533 is a promising alternative for the management of SS and its salivary gland involvement. In considering these agents, the promise of efficacy must be balanced against the harmful effects associated with biologic agents.